hdlforum.org
Glossary
http://www.hdlforum.org/resources/glossary
ATP-binding cassette transporter A1, a cell membrane transporter that facilitates the delivery of cholesterol from cells to lipid-poor apolipoprotein A-I in the extracellular space. ATP-binding cassette transporter G1, a cell membrane transporter that promotes the transfer of cholesterol from cells to large alpha-migrating, spherical HDL. A variant of apoA-I with potent cholesterol efflux capacity. Investigational agents that mimic the effect of apoA-I. A soft fatty waxy substance transported in the bloo...
hdlforum.org
Forgot your Password?
http://www.hdlforum.org/component/user/reset
Please enter the e-mail address for your account. A verification token will be sent to you. Once you have received the token, you will be able to choose a new password for your account. Unless otherwise indicated, opinions expressed in HDL Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the sponsor, publisher, editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
hdlforum.org
Societies
http://www.hdlforum.org/resources/societies
American College of Cardiology. European Society of Cardiology. Association for Clinical Biochemistry. American Society for Biochemistry and Molecular Biology. Head of Lipid Research Group. Click here for the Editorial Advisory Board. REGISTRATION IS FREE TO ALL HEALTHCARE PROFESSIONALS. Supported by an unrestricted medical. Supporters have no editorial influence. Over the content of this website.
hdlforum.org
Viewpoints
http://www.hdlforum.org/ask-the-expert/viewpoints
HPS2-THRIVE: what does it mean for niacin and HDL? Topline results from HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events). The detailed study results are anticipated at this year’s American College of Cardiology meeting. HDL Forum Viewpoint: Future challenges will improving HDL delay progression from metabolic syndrome to diabetes? Here we present the first in a series of commentaries focusing on emerging therapies for raising HDL cholesterol. Despite best...
hdlforum.org
Expert Opinion
http://www.hdlforum.org/ask-the-expert/expert-opinion
Discussion of critical clinical and scientific questions by key opinion leaders. Antonio Gotto, Dean Emeritus, Weill Medical College of Cornell University, New York, USA. Dr Gotto reviews adherence issues in the dyslipidemic patient. This text will be replaced. Professor Ginsberg reviews the evidence for the diabetogenicity of statins - is HDL a factor? This text will be replaced. Do statins raise HDL-C levels? And if so, how? This text will be replaced. This text will be replaced. Unless otherwise indic...
koengland.co.uk
Koengland.co.uk | Web Design & Development . Print Design . Graphic Design .
http://www.koengland.co.uk/sherbornegibbs.html
Sherborne Gibbs Ltd. are publishing firm based in Alcester in the West Midlands. They focus on publication of medical journals and needed to move these publications online. They required one site for their biggest publication - PCCJ Plus. And three break-away sites for their smaller ones - Haematology Now. Koengland.co.uk 2014.
hdlforum.org
Editorial Board
http://www.hdlforum.org/editorial-board
Centre for Vascular Research, Cojoint Professor. University of New South Wales. Centre for Vascular Research, Cojoint Professor. University of New South Wales. Dyslipoproteinemia and Atherosclerosis Research Unit. National Institute for Health and Medical Research (INSERM). Hôpital de la Pitié. Lipoprotein and Atherosclerosis Research. Washington DC, USA. Professor Alberico L. Catapano. Institute of Pharmacological Sciences. Irving Professor of Medicine. Columbia University Medical Center, New York, USA.
hdlforum.org
HDL Forum
http://www.hdlforum.org/index.php
High-density lipoprotein (HDL) have important functions that may help to protect against atherosclerosis. Recent guidelines recognise that HDL cholesterol is an independent cardiovascular risk factor even at target LDL cholesterol. Low HDL cholesterol, often with elevated triglycerides, is the main driver of atherogenic risk in cardiometabolic disease the challenge for the 21st century. Treatments targeting this HDL-related risk may help to reduce cardiovascular risk that persists beyond LDL reduction.
hdlforum.org
Professor John Chapman
http://www.hdlforum.org/professor-john-chapman
Dyslipoproteinemia and Atherosclerosis Research Unit. National Institute for Health and Medical Research (INSERM). Hôpital de la Pitié. Head of Lipid Research Group. Click here for the Editorial Advisory Board. REGISTRATION IS FREE TO ALL HEALTHCARE PROFESSIONALS. Supported by an unrestricted medical. Supporters have no editorial influence. Over the content of this website.
hdlforum.org
Slide Resources
http://www.hdlforum.org/resources/slides
HDL-TG Axis in Metabolic Syndrome. HDL and Atherosclerosis: an overview. HDL cholesterol and cardiovascular risk. Raising HDL cholesterol: therapeutic considerations. Advancing HDL Science: HDL Nomenclature Self-Study Slide Library. Oxford nicotinic acid trial. ARBITER 2 and 3 trials. HATS: HDL Atherosclerosis Treatment Study. FATS: Familial Atherosclerosis Treatment Study. Head of Lipid Research Group. Click here for the Editorial Advisory Board. REGISTRATION IS FREE TO ALL HEALTHCARE PROFESSIONALS.
